Theravance Biopharma TBPH Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's financing cash flow?
- Theravance Biopharma (TBPH) reported financing cash flow of -$5.58M in Q1 2026.
- How has Theravance Biopharma's financing cash flow changed year-over-year?
- Theravance Biopharma's financing cash flow decreased by 553.0% year-over-year, from -$854K to -$5.58M.
- What is the long-term trend for Theravance Biopharma's financing cash flow?
- Over 4 years (2021 to 2025), Theravance Biopharma's financing cash flow has grown at a -56.9% compound annual growth rate (CAGR), from $94.15M to -$3.25M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.